References
- Bullock, R. J., & Batten, D. (1985). It’s just a phase we’re going through: A review and synthesis of OD phase analysis. Group & Organization Studies, 10(4), 383–412. doi:https://doi.org/10.1177/105960118501000403
- Centers for Disease Control & Prevention [CDC]. (2016a). Hepatitis C FAQs for the public. Retrieved from http://www.cdc.gov/hepatitis/hcv/cfaq.htm#overview
- Centers for Disease Control & Prevention [CDC]. (2016b). Hepatitis C and injection drug use. Retrieved from https://www.cdc.gov/hepatitis/hcv/pdfs/FactSheet-PWID.pdf
- Centers for Disease Control & Prevention [CDC]. (2019). Hepatitis C tables and figures – U.S. 2017 surveillance data. Retrieved from https://www.cdc.gov/hepatitis/statistics/2017surveillance/TablesFigures-HepC.htm
- Coyle, C., Viner, K., Hughes, E., Kwakwa, H., Zibbell, J. E., Vellozzi, C., & Holtzman, D. (2015). Identification and linkage to care of HCV-infected persons in five health centers- Philadelphia, Pennsylvania, 2012–2014. MMWR: Morbidity & Mortality Weekly Report, 64(17), 459–463.
- ECHO Chicago (2017, January 31). Series introduction and HCV screening [Webinar]. In HCV case management and clinic capacity building series. Retrieved from http://www.echo-chicago.org/curricula/hepatitis-c-case-managementcapacitybuilding/
- Edlin, B. R. (2016). Access to treatment for hepatitis C virus infection: Time to put patients first. Lancet Infectious Diseases, 16(9), 196–201.
- Illinois Department of Healthcare and Family Services [IHFS]. (2016). General criteria for prior approval of newer direct-acting antivirals (DAA) for hepatitis C. Retrieved from https://www.illinois.gov/hfs/SiteCollectionDocuments/HepatitisC.pdf
- Mayer, K. H., Crawford, P., Dant, L., Gillespie, S., Singal, R., Vandermeer, M., … McBurnie, M. A. (2016). HIV and Hepatitis C virus screening practices in a geographically diverse sample of American community health centers. AIDS Patient Care and STDs, 30(6), 237–246. doi:https://doi.org/10.1089/apc.2015.0314
- Mitchell, G. (2013). Selecting the best theory to implement planned change. Nursing Management, 20(1), 32–37. doi:https://doi.org/10.7748/nm2013.04.20.1.32.e1013
- Schencker, L. (2016, September 12). State switches stance on Hepatitis C drugs, expands access, but not all Medicaid patients qualify. Chicago Tribune. Retrieved from http://www.chicagotribune.com/business/ct-hepatitis-medicaid-drugs-0912-biz-20160909-story.html
- Soumitri, B., Greenwald, R., Grebely, J., Dore, G. J., Swan, T., & Taylor, L. E. (2015). Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of Hepatitis C virus infection in the United States. Annals of Internal Medicine, 163(3), 215–212. doi:https://doi.org/10.7326/M15-0406